menu
    • menu
    [{"orgOrder":0,"company":"AmerisourceBergen","sponsor":"Citius Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Agreement","leadProduct":"Denileukin Diftitox","moa":"Elongation factor 2 | Interleukin-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"AmerisourceBergen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AmerisourceBergen \/ AmerisourceBergen","highestDevelopmentStatusID":"15","companyTruncated":"AmerisourceBergen \/ AmerisourceBergen"},{"orgOrder":0,"company":"AmerisourceBergen","sponsor":"Outlook Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Agreement","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A||VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"AmerisourceBergen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AmerisourceBergen \/ AmerisourceBergen","highestDevelopmentStatusID":"15","companyTruncated":"AmerisourceBergen \/ AmerisourceBergen"}]

    Find Clinical Drug Pipeline Developments & Deals by AmerisourceBergen

    Menu

    AmerisourceBergen

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AmerisourceBergen

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            AmerisourceBergen

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Denileukin Diftitox

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Citius Oncology

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Citius Expands Distribution Network for LYMPHIR with Cencora

                            Details : Under the agreement, Cencora will execute the distribution process of Lymphir (denileukin diftitox). It is being indicated for the treatemnt of Stage I-III cutaneous T-cell lymphoma.

                            Product Name : Lymphir

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            July 15, 2025

                            Lead Product(s) : Denileukin Diftitox

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Citius Oncology

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AmerisourceBergen

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            AmerisourceBergen

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bevacizumab

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Recipient : Outlook Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Outlook Therapeutics® and AmerisourceBergen Announce Strategic Commercialization Agreement for ONS-5010 for t...

                            Details : ONS-5010 is an investigational ophthalmic formulation of bevacizumab under development to be administered as an intravitreal injection for the treatment of wet AMD and other retinal diseases.

                            Product Name : Lytenava

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            September 27, 2022

                            Lead Product(s) : Bevacizumab

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Recipient : Outlook Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth